HCA
RCKT icon

Harbour Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Harbour Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-53,690
Closed -$893K – 304
2024
Q3 		$893K Buy
53,690
+17,510
+48% +$359K 0.21% 110
2024
Q2 		$747K Buy
36,180
+15,025
+71% +$345K 0.18% 122
2024
Q1 		$544K Buy
21,155
+11,330
+115% +$322K 0.13% 165
2023
Q4 		$282K Buy
+9,825
New +$217K 0.08% 217

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harbour Capital Advisors's RCKT Position: Q4 2024 in Review

Harbour Capital Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2024, closing a stake of 53,690 shares — an estimated $893K sold.

Harbour Capital Advisors first reported a position in RCKT in Q4 2023 and held it in 4 quarters. The position peaked at $893K in Q3 2024. 225 funds tracked by Wall St. Rank hold RCKT as of Q4 2024.

  • Harbour Capital Advisors reported no remaining Rocket Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Harbour Capital Advisors sold 53,690 Rocket Pharmaceuticals shares in Q4 2024, an estimated $893K.
  • Harbour Capital Advisors first reported a position in Rocket Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Harbour Capital Advisors's Rocket Pharmaceuticals position peaked at $893K in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2024.

Based on Harbour Capital Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.